NEW YORK (GenomeWeb News) — Sequenom today said it has exclusively licensed IP to a non-invasive prenatal genetic analysis technology from the Chinese University of Hong Kong.
Under the agreement, Sequenom may use the school’s methylation marker and gene expression-analysis IP for fetal nucleic acids in North America, Europe, Australia, and Japan. It also received non-exclusive rights in China.
Sequenom also said the deal includes rights to some methylation and nucleic acid markers.
CEO Harry Stylii said the deal provides Sequenom “an opportunity to expand our technology of fetal DNA to include epigenetic and expression analysis,” which may help develop methods that bypass problems associated with assays for prenatal testing.
The technology Sequenom licensed in the deal adds to the non-invasive prenatal IP the company licensed from Isis Innovation in October 2006.
Financial terms of the agreement were not released.